{"type":"trials","record":{"id":41833,"source_id":"clinicaltrials-gov","external_id":"NCT05571267","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","brief_summary":"The primary objective is to assess the safety of intravitreal (IVT) Zimura® administered in combination with anti-VEGF Therapy (AVASTIN®, EYLEA®, OR LUCENTIS®) in anti-VEGF treatment experienced subjects with neovascular age-related macular degeneration (AMD)","overall_status":"Terminated","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"IVERIC bio, Inc.","enrollment":1,"countries":[],"start_date":"2016-10-20","completion_date":"2018-04-24","last_update_date":"2025-03-13","source_url":"https://clinicaltrials.gov/study/NCT05571267","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 80 Years","comparator":null,"organization":"Astellas Pharma Inc","interventions":["Avacincaptad Pegol","Avastin","Lucentis","Eylea"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Percentage of Participants With >0 Letter Loss — Month 12","Percentage of Participants With >0 Letter Loss — Month 18","Percentage of Participants With >5 Letter Loss — Month 12","Percentage of Participants With >5 Letter Loss — Month 18","Percentage of Participants With >10 Letter Loss — Month 12","Percentage of Participants With >10 Letter Loss — Month 18"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Neovascular Age-Related Macular Degeneration","Avacincaptad Pegol","Avastin","Lucentis","Eylea"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05571267","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2016-10-20 to 2018-04-24","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.878Z","intervention":["Avacincaptad Pegol","Avastin","Lucentis","Eylea"],"participants":1,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Percentage of Participants With >0 Letter Loss — Month 12","Percentage of Participants With >0 Letter Loss — Month 18","Percentage of Participants With >5 Letter Loss — Month 12","Percentage of Participants With >5 Letter Loss — Month 18","Percentage of Participants With >10 Letter Loss — Month 12","Percentage of Participants With >10 Letter Loss — Month 18"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41833","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}